Wedge Capital Management’s AstraZeneca AZN Stock Holding History

Wedge Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-776,692	Closed	-$51M	–	563
2016 Q3	$51M	Sell	776,692 -63,748	-8%	-$4.17M	0.51%	53
2016 Q2	$50.7M	Buy	840,440 +132,400	+19%	+$7.69M	0.53%	49
2016 Q1	$39.9M	Buy	708,040 +115,490	+19%	+$6.94M	0.42%	71
2015 Q4	$40.2M	Sell	592,550 -5,850	-1%	-$384K	0.42%	70
2015 Q3	$38.1M	Sell	598,400 -43,325	-7%	-$2.85M	0.4%	72
2015 Q2	$40.9M	Sell	641,725 -120,200	-16%	-$8.23M	0.4%	92
2015 Q1	$52.1M	Buy	761,925 +48,675	+7%	+$3.38M	0.52%	57
2014 Q4	$50.2M	Buy	+713,250	New	+$51.1M	0.5%	57

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Wedge Capital Management's AZN Position: Q4 2016 in Review

Wedge Capital Management sold out of AstraZeneca (AZN) in Q4 2016, closing a stake of 776,692 shares — an estimated $51M sold.

Wedge Capital Management first reported a position in AZN in Q4 2014 and held it in 8 quarters. The position peaked at $52.1M in Q1 2015. 449 funds tracked by Wall St. Rank hold AZN as of Q4 2016.

Wedge Capital Management reported no remaining AstraZeneca position as of Q4 2016 after selling out during the quarter.
Wedge Capital Management sold 776,692 AstraZeneca shares in Q4 2016, an estimated $51M.
Wedge Capital Management first reported a position in AstraZeneca in Q4 2014 and held it in 8 quarters.
Wedge Capital Management's AstraZeneca position peaked at $52.1M in Q1 2015.
449 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2016.

Based on Wedge Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.